Last reviewed · How we verify
SYL1001
At a glance
| Generic name | SYL1001 |
|---|---|
| Sponsor | Sylentis, S.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome (PHASE3)
- Safety Study of Tivanisiran to Treat Dry Eye (PHASE3)
- HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED) (PHASE3)
- Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain (PHASE2)
- Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain (PHASE1, PHASE2)
- Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SYL1001 CI brief — competitive landscape report
- SYL1001 updates RSS · CI watch RSS
- Sylentis, S.A. portfolio CI